Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
Moodys
Dow
Boehringer Ingelheim

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Interferon beta-1a - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for interferon beta-1a

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Assistance Publique Hopitaux De MarseillePhase 3
Edwin HorwitzPhase 1
Shanghai HEP Pharmaceatical Co., Ltd.Phase 2

See all interferon beta-1a clinical trials

Recent Litigation for interferon beta-1a

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Amgen Inc. v. Accord Healthcare, Inc.2018-06-28
Idenix Pharmaceuticals LLC v. Gilead Sciences, Inc.2014-07-01
Abbott Laboratories v. Watson Laboratories Inc. - Florida2010-01-22

See all interferon beta-1a litigation

Pharmacology for interferon beta-1a

Patent Text Search: US Patents for interferon beta-1a

These patents were identified by searching patent claims

Supplementary Protection Certificates for interferon beta-1a

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2016 Austria   Start Trial PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON, INSVBESONDERE DARUNAVIR-ETHANOLAT; REGISTRATION NO/DATE: EU/1/14/967 (MITTEILUNG) 20141121
00681 Netherlands   Start Trial PRODUCT NAME: SOFOSBUVIR, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140116
2017000002828 Italy   Start Trial PRODUCT NAME: COBICISTAT O UN SALE FARMACEUTICAMENTE ACCETTABILE DELLO STESSO E TENOFOVIR ALAFENAMIDE O UN SALE FARMACEUTICAMENTE ACCETTABILE DELLO STESSO, IN PARTICOLARE TENOFOVIR ALAFENAMIDE FUMARATO(GENVOYA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1061, 20151123
0780 Netherlands   Start Trial PRODUCT NAME: COBICISTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527
17/1999 Austria   Start Trial PRODUCT NAME: INTERFERON ALFACON-1
0160039 00209 Estonia   Start Trial PRODUCT NAME: DAKLIZUMAB;REG NO/DATE: EU/1/16/1107 05.07.2016
1539200/01 Switzerland   Start Trial PRODUCT NAME: DACLIZUMAB BETA; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 66069 26.01.2017
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Dow
AstraZeneca
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.